ArticleBioconjugate chemistry2025
Multicheckpoint Cellular Targeting of siRNAs Using Antibody-Directed Lipid-Polymer Hybrid Nanoparticles.
Article in Bioconjugate chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- RNA therapeutics: current status and future directions.Signal transduction and targeted therapy · 2026Review
- Engineering smart polymeric lipid nanoparticles for breast cancer: AI-guided formulation design, biological barriers, and translational constraints.Journal of nanobiotechnology · 2026Review
- siRNA Nanoparticle Delivery Strategies and Clinical Trial Advances in Tumor Therapy.International journal of molecular sciences · 2026Review
- Advances in Lipid-Polymer Hybrid Nanoparticles: Design Strategies, Functionalization, Oncological and Non-Oncological Clinical Prospects.Pharmaceuticals (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Despite advancements in tissue-specific gene therapy, current technologies struggle to target organs beyond the liver, spleen, and lungs. Passive approaches such as selective organ targeting (SORT) lipids show potential but require time-intensive optimization. Active targeting, exemplified by antibody-drug conjugates (ADCs), offers a modular and effective alternative. Building on this, we developed antibody-functionalized hybrid lipid-polymer nanoparticles for siRNA delivery, targeting cancer-overexpressed receptors such as EGFR and TROP2, prevalent in aggressive cancers like triple-negative breast cancer (TNBC). In addition, to enhance therapeutic safety and efficacy, we integrated multi-siRNA delivery into a multicheckpoint targeting strategy, minimizing reliance on single antigens and reducing off-target risks. Using TNBC cells as a model, this platform demonstrates potential for developing a robust and safe therapeutic approach. In this article, we present our findings that lay the foundation for developing a multicheckpoint strategy to enhance target selectivity in nanomedicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.